HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Oncternal Therapeutics (NASDAQ:ONCT) and maintained a price target of $19.
May 31, 2024 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Oncternal Therapeutics and maintained a price target of $19, indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and a maintained price target of $19 by HC Wainwright & Co. suggests strong confidence in Oncternal Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100